This article is more than 5 years old. Information may no longer be current.
Latanoprostene bunod reduces IOP, ocular hypertension
Click Here to Manage Email Alerts
BOSTON – Once daily latanoprostene bunod 0.024%, taken in the evening, reduced IOP in subjects with open angle glaucoma or ocular hypertension significantly, compared to the IOP-lowering capability of timolol 0.5% twice daily, according to a poster presented by Murray Fingeret, OD, and Jason L. Vittitow, PhD, here at Optometry’s Meeting.
A total of 774 subjects completed 3 months of follow-up across two phase 3, multicenter, parallel-group, non-inferiority studies in which subjects 18 years and older were randomized to double-masked treatment with either latanoprostene bunod (LBN) 0.024% once daily at night or timolol 0.5% twice daily.
Prostaglandins have become a major treatment for glaucoma, but the question is whether or not they can be improved, Fingeret said at a special session featuring the top posters at the meeting.
One of the exciting things about this medication is that it targets one of the causes of the disease, he added.
“All of our drugs right now have not gone after one of the reasons the condition may occur. This drug may,” he said. “We’ll find out more once this particular drug is out and being used.”
In the LBN patients, the reduction in IOP ranged from 7.5 mm Hg to 9.1 mm Hg, with greater reductions compared to timolol, according to the study.
In LBN-treated patients, 20.2% experienced an IOP reduction of at least 25% from baseline vs. 11.2% of the timolol group.
“The drug is a single agent that has been modified with the bunod molecule onto the end, to the latanoprost acid, and what we have is a dual action IOP-lowering agent,” Fingeret said.
Researchers found no safety concerns based on ocular signs, visual acuity or vital signs, they said. – by Abigail Sutton
Reference :
Fingeret M. Current research you should incorporate into your mode of practice now. Presented at: Optometry’s Meeting; June 29–July 2, 2016; Boston.
Disclosure: Fingeret is a consultant for Bausch + Lomb, and Vittitow is an employee of B + L. Latanoprostene bunod is a B + L product that has not yet been FDA approved.